- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- DYNE-251, Placebo
- Drug
- Lead sponsor
- Dyne Therapeutics
- Industry
- Eligibility
- 4 Years to 16 Years · Male only
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 11
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 258
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinsons Disease
- Interventions
- Prasinezumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 27 more
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Placebo (for alirocumab), Atorvastatin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 38
- States / cities
- Tempe, Arizona • Los Angeles, California • Mission Viejo, California + 33 more
- Conditions
- Breast Cancer
- Interventions
- Afuresertib, Afuresertib/placebo
- Drug
- Lead sponsor
- Laekna Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 3 more
- Conditions
- Alzheimer's Disease
- Interventions
- E2814, Lecanemab, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Bradenton, Florida + 15 more
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone
- Drug · Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more
- Conditions
- Higher-risk Myelodysplastic Syndromes
- Interventions
- AK117, Placebo, Azacitidine
- Drug
- Lead sponsor
- Akeso
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 11 more
- Conditions
- Healthy Volunteers, Hypercholesterolemia
- Interventions
- LY3015014, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Miramar, Florida
- Conditions
- Osteoarthritis
- Interventions
- LNA043, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Mesa, California + 20 more
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Secukinumab, Placebo (Pbo)
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 5
- States / cities
- Portland, Oregon • Duncansville, Pennsylvania • Jackson, Tennessee + 2 more
- Conditions
- Ulcerative Colitis
- Interventions
- Ontamalimab, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 16 Years to 81 Years
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 94
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 80 more
- Conditions
- Alzheimer Disease (AD)
- Interventions
- Zagotenemab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Encino, California + 45 more
- Conditions
- Plaque Psoriasis
- Interventions
- Ixekizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Anaheim, California • Beverly Hills, California + 52 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab, Placebo, TCS Cream
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 13 more
- Conditions
- Multiple System Atrophy
- Interventions
- Placebo, TAK-341
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 7
- States / cities
- Farmington Hills, Michigan • Rochester, Minnesota • New York, New York + 4 more
- Conditions
- Heart Failure
- Interventions
- Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Main cohort (Cohort A): Matched placebo, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort C: Matched placebo, Optional Cohort D: Ponsegromab high dose, Optional Cohort D: Matched placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 22
- States / cities
- Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
- Conditions
- Atopic Dermatitis
- Interventions
- Etokimab, Placebo
- Biological · Drug
- Lead sponsor
- AnaptysBio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 34 more
- Conditions
- Primary IgA Nephropathy
- Interventions
- Sefaxersen (RO7434656), Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Glendale, California • Los Angeles, California + 15 more
- Conditions
- Healthy, Chronic Stable Illness
- Interventions
- REGN10933+REGN10987, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 974 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Tempe, Arizona • Rogers, Arkansas • Sacramento, California + 4 more
- Conditions
- Non-small Cell Lung Cancer NSCLC
- Interventions
- Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 9
- States / cities
- Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more
- Conditions
- Sanfilippo Syndrome
- Interventions
- Recombinant human heparan N-sulfatase [rhHNS]
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Months to 48 Months
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Torrance, California • Minneapolis, Minnesota • Chapel Hill, North Carolina
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Astegolimab, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 1,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 36
- States / cities
- Dothan, Alabama • Jasper, Alabama • Mobile, Alabama + 32 more
- Conditions
- Prurigo Nodularis
- Interventions
- barzolvolimab, Matching Placebo
- Biological · Other
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 30 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Itepekimab SAR440340, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 1,234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Fresno, California • Palm Springs, California + 49 more